“The U.S. Food and Drug Administration is warning healthcare professionals about the potential for foreign particle contamination of several products manufactured by Genzyme Corporation that are used to treat rare, serious, and life-threatening diseases. The foreign particles, believed to be found in less than 1% of products based on product lots assessed to date, include stainless steel fragments, non-latex rubber from the vial stopper, and fiber-like material from the manufacturing process and could potentially cause serious adverse events in patients. This problem affects all lots of the below listed products which have the prefix "A" (e.g., Lot A12345). The affected products are manufactured by Genzyme Corporation at their Allston Landing, MA, facility.

The affected products include:

• Cerezyme (imiglucerase) for Gaucher disease
• Fabrazyme (agalsidase beta) for Fabry disease
• Myozyme/Lumizyme (alglucosidase alpha) for Pompe disease
• Aldurazyme (laronidase) for mucoploysaccharidosis I
• Thyrogen (thyrotropin alpha) used as an adjunctive diagnostic tool and treatment for thyroid cancer

At this time, no adverse event reports related to potential foreign particle contamination have been received by FDA. However, healthcare professionals should be alert for the development of adverse events.

For additional information, including considerations for healthcare professionals, please visit FDA's Web site.

To report any unexpected adverse or serious events associated with the use of these products, please contact the FDA MedWatch program and complete a form online at http://www.fda.gov/medwatch/report/hcp.htm or report by fax to 1-800-FDA-0178, by mail using the postage-paid address form provided online, or by telephone to 1-800-FDA-1088.”

La Genzyme Corporation ha inviato una lettera a tutti i medici interessati con le indicazioni ed i provvedimenti da assumere in caso di uso del prodotto farmaceutico Thyrogen e che trovate nell’allegato: Foreign Particles: ThyrogenR (thyrotropin alfa for injection) Letter from Genzyme (PDF File, 144 KB)

Alfredo Pontecorvi
Segretario Generale SIE

Pubblicati i nuovi livelli essenziali di assistenza (LEA) i nuovi elenchi delle malattie croniche e rare esentate dal pagamento del ticket e le prestazioni relative alla specialistica ambulatoriale